Google
SEELQ 株価分析 — Seelos Therapeutics, Inc. (Healthcare >> Biotechnology)
SEELQ に関するよくある質問
SEELQのROE（自己資本利益率）は？
Seelos Therapeutics, Inc.のROEは-14.54%です。
SEELQの配当利回りは？
Seelos Therapeutics, Inc.の配当利回りは0.00%です。
SEELQの品質スコア（Quality Score）は？
当社のAIはSEELQの総合財務品質を100点中38点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
SEELQは今が買い時ですか？
当社AIのタイミングスコアは100点中0点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
SEELQはどのセクターに属しますか？
Seelos Therapeutics, Inc.はHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
SEELQ AI Analysis Summary
Our AI summary for SEELQ: Seelos Therapeutics, Inc. (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -14.54%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 0/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.00
Price
0
(0%)
Day Change
|
|
|---|
SEELQ, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | N/A |
| PBV / Sector |
N/A / 44,105.10
|
| Earning Per Share | 7.05 |
| PE / Sector |
N/A / 19.37
|
| PEG or PE/Growth / Sector |
N/A / 1.06
|
| Average 1M Daily Value |
0.002225000000
GREAT
|
| Average 1W Daily Value |
0.000000000000
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
8% |
| 登録情報 |
| Analyze Date | 2026-08-06 08:00:39 |
| Symbol | SEELQ |
| Name | SEELOS THERAPEUTICS, INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 0.58 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | N/A / 9,702.21 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 300 Park Avenue, New York, NY, United States, 10022
Phone: 646 293 2100
Website: https://seelostherapeutics.com
Sector: Healthcare >> Biotechnology
Description: Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007, a peptidic inhibitor for NACore Parkinson disease; and SLS-009, a protein targeted autophagy for Alzheimer disease. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York. On November 16, 2024, Seelos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
